keyword
MENU ▼
Read by QxMD icon Read
search

Alan F. List

keyword
https://www.readbyqxmd.com/read/27883945/recent-advances-in-the-treatment-of-lower-risk-non-del-5q-myelodysplastic-syndromes-mds
#1
REVIEW
Antonio Almeida, Pierre Fenaux, Alan F List, Azra Raza, Uwe Platzbecker, Valeria Santini
Patients with lower-risk myelodysplastic syndromes (MDS) are affected primarily by symptoms of chronic anemia and fatigue rather than progression to acute myeloid leukemia. Severe thrombocytopenia, although less common in lower-risk MDS, is associated with increased risk of bleeding. For anemic patients, the principal aim of treatment is to improve anemia and decrease red blood cell transfusions. For transfusion-dependent patients with lower-risk MDS without chromosome 5q deletion [non-del(5q) MDS], there are limited effective treatments...
November 13, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27862777/deriving-structural-information-from-experimentally-measured-data-on-biomolecules
#2
REVIEW
Wilfred F van Gunsteren, Jane R Allison, Xavier Daura, Jožica Dolenc, Niels Hansen, Alan E Mark, Chris Oostenbrink, Victor H Rusu, Lorna J Smith
During the past half century, the number and accuracy of experimental techniques that can deliver values of observables for biomolecular systems have been steadily increasing. The conversion of a measured value Q(exp) of an observable quantity Q into structural information is, however, a task beset with theoretical and practical problems: 1) insufficient or inaccurate values of Q(exp) , 2) inaccuracies in the function Q(r→) used to relate the quantity Q to structure r→ , 3) how to account for the averaging inherent in the measurement of Q(exp) , 4) how to handle the possible multiple-valuedness of the inverse r→(Q) of the function Q(r→) , to mention a few...
November 8, 2016: Angewandte Chemie
https://www.readbyqxmd.com/read/27737891/the-nlrp3-inflammasome-functions-as-a-driver-of-the-myelodysplastic-syndrome-phenotype
#3
Ashley A Basiorka, Kathy L McGraw, Erika A Eksioglu, Xianghong Chen, Joseph Johnson, Ling Zhang, Qing Zhang, Brittany A Irvine, Thomas Cluzeau, David A Sallman, Eric Padron, Rami Komrokji, Lubomir Sokol, Rebecca C Coll, Avril A B Robertson, Matthew A Cooper, John L Cleveland, Luke A O'Neill, Sheng Wei, Alan F List
Despite genetic heterogeneity, myelodysplastic syndromes (MDS) share features of cytological dysplasia and ineffective hematopoiesis. We report that a hallmark of MDS is activation of the NLRP3 inflammasome, which drives clonal expansion and pyroptotic cell death. Independent of genotype, MDS hematopoietic stem/progenitor cells (HSPC) overexpress inflammasome proteins and manifest activated NLRP3 complexes that direct activation of caspase-1, generation of IL-1β and IL-18 and pyroptotic cell death. Mechanistically, pyroptosis is triggered by the alarmin S100A9 that is found in excess in MDS HSPC and bone marrow plasma...
October 13, 2016: Blood
https://www.readbyqxmd.com/read/27707735/when-clinical-heterogeneity-exceeds-genetic-heterogeneity-thinking-outside-the-genomic-box-in-chronic-myelomonocytic-leukemia
#4
Markus Ball, Alan F List, Eric Padron
Exome sequencing studies in Chronic Myelomonocytic Leukemia (CMML) illustrate a mutational landscape characterized by few somatic mutations involving a subset of recurrent gene mutations in ASXL1, SRSF2, and TET2, each approaching 40% in incidence. This has led to the clinical implementation of next generation sequencing panels that effectively identify clonal monocytosis and complement clinical prognostic scoring systems in most patients. However, most murine models based on single gene mutations fail to recapitulate the CMML phenotype and many gene mutations are loss-of-function making the identification of traditional therapeutic vulnerabilities challenging...
October 5, 2016: Blood
https://www.readbyqxmd.com/read/27521328/eltrombopag-use-in-patients-with-chronic-myelomonocytic-leukemia-cmml-a-cautionary-tale
#5
Hanadi Ramadan, Vu H Duong, Najla Al Ali, Eric Padron, Ling Zhang, Jeffrey E Lancet, Alan F List, Rami S Komrokji
INTRODUCTION: Eltrombopag used for thrombocytopenia in myelodysplastic syndrome (MDS) patients is being explored in clinical trials including those with chronic myelomonocytic leukemia (CMML). PATIENTS AND METHODS: We report our experience treating patients with CMML enrolled in a sequential 2-stage dose escalation study with eltrombopag in patients with MDS after hypomethylating agent failure. Patients with CMML were compared with patients with MDS in respect to response and adverse events...
August 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27521304/proceedings-of-the-third-annual-meeting-of-the-society-of-hematologic-oncology
#6
EDITORIAL
Alan F List, Hagop Kantarjian, Emil J Freireich
No abstract text is available yet for this article.
August 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27418649/mutational-correlates-of-response-to-hypomethylating-agent-therapy-in-acute-myeloid-leukemia
#7
LETTER
Catherine C Coombs, David A Sallman, Sean M Devlin, Shweta Dixit, Abhinita Mohanty, Kristina Knapp, Najla H Al Ali, Jeffrey E Lancet, Alan F List, Rami S Komrokji, Eric Padron, Maria E Arcila, Virginia M Klimek, Marcel R M van den Brink, Martin S Tallman, Ross L Levine, Raajit K Rampal, Franck Rapaport
No abstract text is available yet for this article.
November 2016: Haematologica
https://www.readbyqxmd.com/read/27225531/improved-intra-array-and-interarray-normalization-of-peptide-microarray-phosphorylation-for-phosphorylome-and-kinome-profiling-by-rational-selection-of-relevant-spots
#8
Jetse Scholma, Gwenny M Fuhler, Jos Joore, Marc Hulsman, Stefano Schivo, Alan F List, Marcel J T Reinders, Maikel P Peppelenbosch, Janine N Post
Massive parallel analysis using array technology has become the mainstay for analysis of genomes and transcriptomes. Analogously, the predominance of phosphorylation as a regulator of cellular metabolism has fostered the development of peptide arrays of kinase consensus substrates that allow the charting of cellular phosphorylation events (often called kinome profiling). However, whereas the bioinformatical framework for expression array analysis is well-developed, no advanced analysis tools are yet available for kinome profiling...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27197154/lenalidomide-stabilizes-the-erythropoietin-receptor-by-inhibiting-the-e3-ubiquitin-ligase-rnf41
#9
Ashley A Basiorka, Kathy L McGraw, Leentje De Ceuninck, Lori N Griner, Ling Zhang, Justine A Clark, Gisela Caceres, Lubomir Sokol, Rami S Komrokji, Gary W Reuther, Sheng Wei, Jan Tavernier, Alan F List
In a subset of patients with non-del(5q) myelodysplastic syndrome (MDS), lenalidomide promotes erythroid lineage competence and effective erythropoiesis. To determine the mechanism by which lenalidomide promotes erythropoiesis, we investigated its action on erythropoietin receptor (EpoR) cellular dynamics. Lenalidomide upregulated expression and stability of JAK2-associated EpoR in UT7 erythroid cells and primary CD71+ erythroid progenitors. The effects of lenalidomide on receptor turnover were Type I cytokine receptor specific, as evidenced by coregulation of the IL3-Rα receptor but not c-Kit...
June 15, 2016: Cancer Research
https://www.readbyqxmd.com/read/27081179/immunohistochemical-pattern-of-p53-is-a-measure-of-tp53-mutation-burden-and-adverse-clinical-outcome-in-myelodysplastic-syndromes-and-secondary-acute-myeloid-leukemia
#10
LETTER
Kathy L McGraw, Johnny Nguyen, Rami S Komrokji, David Sallman, Najla H Al Ali, Eric Padron, Jeffrey E Lancet, Lynn C Moscinski, Alan F List, Ling Zhang
No abstract text is available yet for this article.
August 2016: Haematologica
https://www.readbyqxmd.com/read/26992944/the-efficacy-of-current-prognostic-models-in-predicting-outcome-of-patients-with-myelodysplastic-syndromes-at-the-time-of-hypomethylating-agent-failure
#11
LETTER
Aziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, John Barnard, Gail J Roboz, David P Steensma, Amy E DeZern, Katrina Zell, Cassie Zimmerman, Najla Al Ali, Elias Jabbour, Molly D Greenberg, Hagop M Kantarjian, Jaroslaw P Maciejewski, Alan F List, Mikkael A Sekeres
No abstract text is available yet for this article.
June 2016: Haematologica
https://www.readbyqxmd.com/read/26944474/prospective-international-validation-of-the-quality-of-life-in-myelodysplasia-scale-qualms
#12
Gregory A Abel, Fabio Efficace, Rena J Buckstein, Sara Tinsley, Joseph G Jurcic, Yolanda Martins, David P Steensma, Corey D Watts, Azra Raza, Stephanie J Lee, Alan F List, Robert J Klaassen
Disease-specific measures of quality of life can improve assessment of disease-related symptoms and psychosocial sequelae. We report on the development and validation of the Quality of Life in Myelodysplasia Scale (QUALMS), a 38-item assessment tool for patients with myelodysplastic syndromes (MDS). In 2014-2015, a multi-center cohort of patients with myelodysplasia completed the QUALMS, as well as the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and the Functional Assessment of Cancer Therapy Anemia Scale (FACT-An); a second administration was undertaken three to six months later...
June 2016: Haematologica
https://www.readbyqxmd.com/read/26875020/autoimmune-diseases-and-myelodysplastic-syndromes
#13
COMPARATIVE STUDY
Rami S Komrokji, Austin Kulasekararaj, Najla H Al Ali, Shahram Kordasti, Emily Bart-Smith, Benjamin M Craig, Eric Padron, Ling Zhang, Jeffrey E Lancet, Javier Pinilla-Ibarz, Alan F List, Ghulam J Mufti, Pearlie K Epling-Burnette
Immune dysregulation and altered T-cell hemostasis play important roles in the pathogenesis of myelodysplastic syndromes (MDS). Recent studies suggest an increased risk of MDS among patients with autoimmune diseases. Here, we investigated the prevalence of autoimmune diseases among MDS patients, comparing characteristics and outcomes in those with and without autoimmune diseases. From our study group of 1408 MDS patients, 391 (28%) had autoimmune disease, with hypothyroidism being the most common type, accounting for 44% (n = 171) of patients (12% among all MDS patients analyzed)...
May 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/26858309/a-multi-institution-phase-i-trial-of-ruxolitinib-in-patients-with-chronic-myelomonocytic-leukemia-cmml
#14
Eric Padron, Amy Dezern, Marcio Andrade-Campos, Kris Vaddi, Peggy Scherle, Qing Zhang, Yan Ma, Maria E Balasis, Sara Tinsley, Hanadi Ramadan, Cassandra Zimmerman, David P Steensma, Gail J Roboz, Jeffrey E Lancet, Alan F List, Mikkael A Sekeres, Rami S Komrokji
PURPOSE: To conduct a phase I clinical trial exploring the safety and efficacy of ruxolitinib, a JAK1/2 inhibitor, for chronic myelomonocytic leukemia (CMML). EXPERIMENTAL DESIGN: Patients with CMML-1 were included without regard to previous therapy. Key exclusion criteria included an absolute neutrophil count (ANC) <0.25 × 10(3) cells/dL and a platelet count <35 × 10(3) cells/dL. Four cohorts were enrolled using a "rolling six" study design, with doses ranging from 5 to 20 mg twice daily of ruxolitinib in 5-mg dose escalations...
August 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/26823078/prioritization-of-anti-malarial-hits-from-nature-chemo-informatic-profiling-of-natural-products-with-in-vitro-antiplasmodial-activities-and-currently-registered-anti-malarial-drugs
#15
Samuel Ayodele Egieyeh, James Syce, Sarel F Malan, Alan Christoffels
BACKGROUND: A large number of natural products have shown in vitro antiplasmodial activities. Early identification and prioritization of these natural products with potential for novel mechanism of action, desirable pharmacokinetics and likelihood for development into drugs is advantageous. Chemo-informatic profiling of these natural products were conducted and compared to currently registered anti-malarial drugs (CRAD). METHODS: Natural products with in vitro antiplasmodial activities (NAA) were compiled from various sources...
2016: Malaria Journal
https://www.readbyqxmd.com/read/26777537/outcomes-of-patients-with-myelodysplastic-syndromes-who-achieve-stable-disease-after-treatment-with-hypomethylating-agents
#16
Aziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, John Barnard, Najla H Al Ali, Gail J Roboz, David P Steensma, Amy E DeZern, Cassie Zimmerman, Elias J Jabbour, Katrina Zell, Alan F List, Hagop M Kantarjian, Jaroslaw P Maciejewski, Rami S Komrokji
Treatment with hypomethylating agents (HMAs) improves overall survival (OS) in patients who achieve a response of stable disease (SD) or better (complete remission [CR], partial remission [PR], or hematologic improvement [HI]). It is not well established if patients who achieve SD at 4-6 months of therapy should be offered different therapies to optimize their response or continue with the same regimen. Clinical data were obtained from the MDS Clinical Research Consortium database. SD was defined as no evidence of progression and without achievement of any other responses...
February 2016: Leukemia Research
https://www.readbyqxmd.com/read/26701551/a-checklist-of-the-new-world-species-of-tillinae-coleoptera-cleridae-with-an-illustrated-key-to-genera-and-new-country-records
#17
Alan F Burke, John M Leavengood, Gregory Zolnerowich
This checklist presents the distribution of the checkered beetle subfamily Tillinae (Coleoptera: Cleridae) in the New World. Information for 164 species and 2 subspecies from 11 genera is included. The data are based on an extensive survey of material collected throughout the Americas, descriptions of new species, a number of revisionary works, data from museum specimens, as well as unpublished checklists. Cymatodera, the most speciose tilline genus in the New World, has its greatest diversity in Mexico where 100 of the 134 recognized species are known to occur...
December 21, 2015: Zootaxa
https://www.readbyqxmd.com/read/26684796/safety-assessment-of-boron-nitride-as-used-in-cosmetics
#18
REVIEW
Monice M Fiume, Wilma F Bergfeld, Donald V Belsito, Ronald A Hill, Curtis D Klaassen, Daniel C Liebler, James G Marks, Ronald C Shank, Thomas J Slaga, Paul W Snyder, F Alan Andersen
The Cosmetic Ingredient Review Expert Panel (Panel) assessed the safety of boron nitride which functions in cosmetics as a slip modifier (ie, it has a lubricating effect). Boron nitride is an inorganic compound with a crystalline form that can be hexagonal, spherical, or cubic; the hexagonal form is presumed to be used in cosmetics. The highest reported concentration of use of boron nitride is 25% in eye shadow formulations. Although boron nitride nanotubes are produced, boron nitride is not listed as a nanomaterial used in cosmetic formulations...
November 2015: International Journal of Toxicology
https://www.readbyqxmd.com/read/26578796/reduced-dock4-expression-leads-to-erythroid-dysplasia-in-myelodysplastic-syndromes
#19
Sriram Sundaravel, Ryan Duggan, Tushar Bhagat, David L Ebenezer, Hui Liu, Yiting Yu, Matthias Bartenstein, Madhu Unnikrishnan, Subhradip Karmakar, Ting-Chun Liu, Ingrid Torregroza, Thomas Quenon, John Anastasi, Kathy L McGraw, Andrea Pellagatti, Jacqueline Boultwood, Vijay Yajnik, Andrew Artz, Michelle M Le Beau, Ulrich Steidl, Alan F List, Todd Evans, Amit Verma, Amittha Wickrema
Anemia is the predominant clinical manifestation of myelodysplastic syndromes (MDS). Loss or deletion of chromosome 7 is commonly seen in MDS and leads to a poor prognosis. However, the identity of functionally relevant, dysplasia-causing, genes on 7q remains unclear. Dedicator of cytokinesis 4 (DOCK4) is a GTPase exchange factor, and its gene maps to the commonly deleted 7q region. We demonstrate that DOCK4 is underexpressed in MDS bone marrow samples and that the reduced expression is associated with decreased overall survival in patients...
November 17, 2015: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/26416416/tp53-and-mdm2-single-nucleotide-polymorphisms-influence-survival-in-non-del-5q-myelodysplastic-syndromes
#20
Kathy L McGraw, Thomas Cluzeau, David A Sallman, Ashley A Basiorka, Brittany A Irvine, Ling Zhang, P K Epling-Burnette, Dana E Rollison, Mar Mallo, Lubomir Sokol, Francesc Solé, Jaroslaw Maciejewski, Alan F List
P53 is a key regulator of many cellular processes and is negatively regulated by the human homolog of murine double minute-2 (MDM2) E3 ubiquitin ligase. Single nucleotide polymorphisms (SNPs) of either gene alone, and in combination, are linked to cancer susceptibility, disease progression, and therapy response. We analyzed the interaction of TP53 R72P and MDM2 SNP309 SNPs in relationship to outcome in patients with myelodysplastic syndromes (MDS). Sanger sequencing was performed on DNA isolated from 208 MDS cases...
October 27, 2015: Oncotarget
keyword
keyword
116323
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"